Contact Us

The choice depends on whether you are studying combined iRhom function for ADAM17/TACE regulation or distinguishing iRhom-mediated shedding from iRhom-independent processes. The Double Knockout line is uniquely valuable for asking whether ADAM17 maturation and activity are required for these processes — combined iRhom1 + iRhom2 loss essentially eliminates ADAM17 function (ADAM17 fails to exit the ER without iRhom partners), producing an ADAM17 functional null without disrupting the ADAM17 gene itself. Single-iRhom rescue (iRhom1 alone or iRhom2 alone) in the double knockout enables paralog-specific functional studies. For TACE/ADAM17 biology research, the EDITGENE RHBDF1 & RHBDF2 Double Knockout in HEK293 is the gold-standard genetic tool — it produces a functional ADAM17 null and enables clean single-paralog rescue. This product complements the parallel double knockout in A-549. Rescue with iRhom1 alone, iRhom2 alone, or both enables comprehensive paralog dissection — the design for distinguishing iRhom1-versus iRhom2-specific TACE substrate selection. Rescue with iRhom catalytically-dead variants tests whether maturation chaperone activity is sufficient.

Yes, and rescue experiments are uniquely valuable in this lung-cancer double knockout: • Single-iRhom rescue: re-introduction of iRhom1 alone or iRhom2 alone enables paralog-specific functional dissection in lung cancer context — the gold-standard design. • Lung cancer-specific readouts: rescue should restore EGFR ligand shedding, autocrine EGFR signaling, and lung cancer-relevant proliferation/migration phenotypes. • Construct design: codon-modified RHBDF1 or RHBDF2 sequences with small C-terminal tags (FLAG, HA). • Therapeutic context: paralog-specific rescue informs which iRhom should be targeted for lung cancer ADAM17 modulation strategies. A-549 transduces efficiently with lentivirus and supports systematic paralog-specific rescue experiments in a lung cancer-relevant background.

The choice depends on whether you are studying combined iRhom-ADAM17 function in lung cancer biology or testing TACE-mediated EGFR ligand shedding's contribution to NSCLC progression. The Double Knockout line is uniquely valuable for asking whether ADAM17 function is required for lung cancer cell phenotypes — combined iRhom1 + iRhom2 loss creates a functional ADAM17 null in a lung cancer context. Single-iRhom rescue in the double knockout enables paralog-specific lung cancer studies. For lung cancer ADAM17 research, the EDITGENE RHBDF1 & RHBDF2 Double Knockout in A-549 is the gold-standard genetic tool — it produces functional ADAM17 disruption in NSCLC context and enables clean single-paralog rescue for paralog-specific lung cancer biology studies. This product complements the parallel double knockout in HEK293. The model is valuable for studying ADAM17 inhibitor mechanisms (e.g., aderbasib, INCB7839) and for testing tumor cell-intrinsic ADAM17/iRhom contributions to NSCLC biology distinct from immune cell-derived effects.

Yes, and rescue experiments are uniquely powerful in this double knockout background: • Single-RXR rescue: re-introduction of RXRA alone or RXRB alone in the double knockout enables isoform-specific functional dissection — the gold-standard experimental design for redundant nuclear receptor paralogs. • Construct design: codon-modified RXRA or RXRB sequences with small C-terminal tags (FLAG, HA). Preserve all nuclear receptor functional domains. • DNA-binding-deficient and ligand-binding-deficient rescue: structure-function variants enable dissection of RXR-specific activities in the clean double-knockout background. • Functional readout: rescue should restore RAR-RXR retinoid signaling (DR5 reporter), PPAR-RXR lipid metabolism signaling (DR1 reporter), and other partnered nuclear receptor activities. A-549 transduces efficiently with lentivirus and supports systematic single-paralog rescue experiments that would be difficult to interpret in single-knockout backgrounds with paralog compensation.

The choice depends on whether you are studying combined RXR-mediated nuclear receptor signaling in lung cancer biology or distinguishing RXR functions from RXRG-independent processes. The Double Knockout line is uniquely valuable for asking whether RXR-mediated transcription is required for these processes — combined RXRA + RXRB loss eliminates the dominant RXR partners in most non-hematopoietic cells, leaving only minimal RXRG (typically tissue-restricted) compensation. Overexpression of either RXR isoform in the double knockout enables isoform-specific functional dissection. For lung cancer nuclear receptor research, the EDITGENE RXRA & RXRB Double Knockout in A-549 is highly informative — A-549 is a workhorse NSCLC model, and the double knockout disrupts retinoid X receptor partnerships with RAR (retinoid signaling), PPAR (lipid metabolism), LXR (cholesterol homeostasis), and other partners simultaneously. Single-RXR rescue (RXRA alone or RXRB alone) in the double knockout is the gold-standard experimental design for distinguishing paralog-specific functions. The knockout is valuable for studying bexarotene (Targretin), RXR-selective rexinoid mechanism, and emerging RXR-targeted therapeutics.

Yes. As a FYVE domain protein, ZFYVE28 rescue experiments require specific design considerations: • Construct design: use a codon-modified ZFYVE28 sequence. Tag position is critical — the FYVE domain mediates membrane recruitment via phosphoinositide binding, and N-terminal tags can disrupt this function. C-terminal tagging is strongly preferred. • Domain mutant rescue: a FYVE domain-binding-defective mutant (typically a conserved cysteine mutation that abolishes Zn²⁺ coordination) is essential as a specificity control. This distinguishes phenotypes dependent on endosomal recruitment from those mediated by other regions of the protein. • Localization validation: confirm that exogenous wild-type ZFYVE28 recovers endosomal localization (co-staining with EEA1 or Rab5) before assessing functional rescue. • Delivery method: BV-2 is a partially adherent murine microglial line with moderate transfection efficiency. Lentiviral transduction is the recommended approach; transient transfection is acceptable for short-term localization assays but not for inflammatory stimulation experiments requiring stable expression. Polyclonal rescue pools are generally adequate for BV-2 given its phenotypic homogeneity in inflammatory assays.

The choice depends on the experimental question. The Knockout line is appropriate for asking whether ZFYVE28 is required for endosomal sorting, trafficking, or microglial functions such as phagocytosis. Overexpression is appropriate when asking whether forced ZFYVE28 expression is sufficient to alter endosomal compartment dynamics or to modulate inflammatory signaling. For an emerging factor with limited prior functional characterization, the EDITGENE Knockout line is the more conservative starting point — loss-of-function phenotypes provide clearer interpretive ground than overexpression artifacts, which are common for FYVE domain proteins due to their membrane recruitment behavior. Rescue with wild-type or FYVE-domain mutant constructs is particularly valuable here for assigning function to the phosphoinositide-binding domain.

Yes. HVCN1 rescue experiments require attention to voltage-gated channel architecture: • Construct design: use a codon-modified HVCN1 sequence with a small intracellular tag (FLAG, HA). HVCN1 has four transmembrane domains (S1-S4) including the voltage-sensing S4 with characteristic positive charges — preserve membrane topology. • Non-conducting rescue: D112A or N214R/D185A pore-related residue mutations abolish H+ conduction and serve as the standard specificity control. • Functional readout: rescue should restore voltage-gated H+ currents measured by patch clamp and NOX2-supported respiratory burst. BV-2-specific considerations: • BV-2 is an immortalized murine microglial cell line (v-raf/v-myc transformed C57BL/6 microglia) — the most widely used continuous microglial cell line for in vitro neuroimmunology research. • Lentiviral transduction is supported with moderate efficiency; characterize basal microglial activation state (M1/M2 markers) before phenotypic assays. • BV-2 retains key microglial markers (CD11b, Iba1, CD68) and TLR/inflammasome responses, but immortalization may alter some primary microglial features — confirm relevant phenotypes in independent assays.

The choice depends on whether you are studying HVCN1 (Hv1, voltage-gated proton channel 1)'s role as the principal voltage-gated proton channel supporting NADPH oxidase activity or modeling its functions in microglial respiratory burst. The Knockout line is the standard tool for asking whether HVCN1 is required for these processes — HVCN1 is a voltage-gated proton-selective channel that compensates for the electrogenic and pH effects of NADPH oxidase (NOX2) activity, supporting sustained respiratory burst in phagocytes and microglia. Overexpression is useful for studying HVCN1 in heterologous expression contexts. For microglial biology research, the EDITGENE HVCN1 Knockout in BV-2 is uniquely valuable — BV-2 is the most widely used microglial cell line, and HVCN1 is critical for microglial NOX2-driven ROS production implicated in neuroinflammation, ischemic stroke, and neurodegenerative disease. Rescue with wild-type or non-conducting HVCN1 enables structure-function studies. The knockout is a critical specificity tool for HVCN1 inhibitors (5-chloro-2-guanidinobenzimidazole/ClGBI, AbD17561) in development for neuroinflammation and ischemic brain injury — HVCN1 has emerged as a CNS-targeted therapeutic strategy for reducing oxidative damage.

The choice depends on whether you are studying FOXN3 (forkhead box N3, CHES1)'s role as a checkpoint suppressor or its emerging functions in glucose metabolism and hepatic biology. The Knockout line is the standard tool for asking whether FOXN3 is required for these processes — FOXN3 is a forkhead transcription factor originally identified as a checkpoint suppressor in S. cerevisiae complementation; FOXN3 has emerged as a regulator of hepatic glucose production with FOXN3 polymorphisms associated with fasting glucose in human GWAS. Overexpression is useful for studying FOXN3 in heterologous expression contexts. For hepatic metabolism research, the EDITGENE FOXN3 Knockout in Hep-G2 is highly relevant — Hep-G2 is a hepatocellular carcinoma cell line and FOXN3 has been characterized as a regulator of hepatic glucose production. This product complements the parallel FOXN3 Knockout in A-549 (also available) for hepatic versus lung cancer cross-validation. Rescue with wild-type FOXN3 is the standard specificity control. The knockout is valuable for studying FOXN3-dependent hepatic gene regulation, fasting glucose biology, and emerging FOXN3-related metabolic disease research.

Yes. FOXN3 rescue experiments require attention to forkhead transcription factor architecture: • Construct design: use a codon-modified FOXN3 sequence with a small C-terminal tag (FLAG, HA). FOXN3 has central forkhead DNA-binding domain and N/C-terminal regulatory regions — preserve all elements. • DNA-binding-deficient rescue: forkhead domain mutations abolish DNA binding and serve as the standard specificity control. • Functional readout: rescue should restore FOXN3-dependent transcriptional programs in hepatocellular context. Hep-G2-specific considerations: • Hep-G2 is a human hepatocellular carcinoma cell line widely used for hepatocyte differentiation, drug metabolism, and liver biology research. • Lentiviral transduction is supported with moderate efficiency. • Hep-G2 retains many hepatocyte features (albumin synthesis, CYP450 expression, transferrin synthesis) and serves as a complementary HCC model to Huh-7.

Yes, with important considerations specific to lncRNA rescue: • Construct design: TP53TG1 is a long non-coding RNA — rescue requires careful preservation of the full RNA structure rather than coding sequence considerations. Use the validated TP53TG1 transcript sequence with no tag-related modifications. • Expression strategy: stable expression from RNA polymerase II promoters (CMV, EF1α) with optimized 5' caps and poly(A) signals is preferred over polymerase III systems for full-length lncRNA rescue. • Functional domain rescue: where TP53TG1 functional domains have been mapped (e.g., YBX1-binding regions), truncation or deletion constructs can distinguish functional regions. • Functional readout: rescue should restore YBX1 sequestration (subcellular fractionation) and YBX1 target gene regulation, in addition to p53 response amplification. A-549 supports stable lncRNA expression with standard lentiviral systems; copy number titration may be necessary to approximate endogenous TP53TG1 levels.

The choice depends on whether you are studying TP53TG1's role as a p53-induced long non-coding RNA or its tumor-suppressive functions in cancer. The Knockout line is appropriate for asking whether TP53TG1 lncRNA is required for downstream p53 response programs — particularly relevant in A-549, which has TP53 wild-type status (relatively rare among lung cancer lines). Overexpression is useful for testing whether elevated TP53TG1 is sufficient to recapitulate p53-induced phenotypes. For p53 pathway research, the EDITGENE TP53TG1 Knockout in A-549 is particularly informative because A-549's intact p53 status allows the contribution of TP53TG1 to be assessed in a p53-competent background — many lung cancer lines have p53 mutations that complicate this analysis. Rescue experiments for lncRNAs require careful design — typically using stable lncRNA expression from controlled promoters.

Yes. iRhom2 rescue experiments are well-established for ADAM17 regulation research: • Construct design: use a codon-modified RHBDF2 sequence with a small C-terminal tag (FLAG, HA). iRhom2 has the rhomboid family 7-transmembrane architecture but lacks catalytic activity (pseudoenzyme) — preserve all elements. • N-terminal cytoplasmic domain mutant rescue: phospho-resistant or phospho-mimetic mutations at key sites in the N-terminal cytoplasmic domain enable studies of 14-3-3-regulated activation. • Tylosis-associated mutation rescue: TOC-associated RHBDF2 mutations (I186T, P189L, D188N) introduced for disease genotype-function studies. • Functional readout: rescue should restore ADAM17 Golgi maturation (mature ADAM17 Western blot) and substrate ectodomain shedding activity. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying RHBDF2 (iRhom2)'s role as a tissue-specific regulator of ADAM17/TACE-mediated ectodomain shedding or its emerging functions in inflammatory disease and cancer. The Knockout line is the standard tool for asking whether iRhom2 is required for ADAM17 maturation and substrate selection — iRhom2 is critical for TNF-α release from immune cells and EGFR ligand shedding in epithelial contexts. Overexpression is useful for studying iRhom2's tissue-specific TACE regulation. For inflammation and EGFR signaling research, the EDITGENE RHBDF2 Knockout in HEK293 is a mechanistic platform — HEK293 has been extensively used for iRhom-ADAM17 biochemistry and structure-function studies. This product complements the parallel RHBDF2 Knockout in A-549 and the RHBDF1 & RHBDF2 Double Knockouts (also available); HEK293 is preferred for biochemistry and rescue studies given its high transfection efficiency. RHBDF2 mutations cause tylosis with esophageal cancer (TOC) and curly coat syndrome — disease variant rescue enables genotype-function studies.